References

Abbott JA, Garry R. The surgical management of menorrhgia. Hum.

Reprod. Update 2002; 8 (I): 68-78.

ACOG. practice bulletin: Intrauterine device. Int. J. Gynaecol. Obstet. 2005;

105:223-32.

ACOG practice bulletin : management of anovulatory bleeding . Int. J.

Gynaecol. Obstet . 2001; 72: 263- 271.

Ahmed A, Smith SK. Platelet-activating factor stimulates phospholipase C

activity in human endometrium. J. Cell Physiol. 1992; 152: 207-

214

Alecozay AA, Delon FD, Harper MJ et al. Platelet activating factor (PAF)

in human endometrium. Bio. Reprod. 1988; 38 (suppl. I): 78

Alecozay AA, Harper MJ, Schenken RS, et al. Paracrine interactions

between platelet activating factor and prostaglandins in hormonally

treated luteal phase endometrium. J. Reprod. Fertil. 1991; 91:301-

12.

Andersson K. The levonorgestrel intrauterine system: more than a

contraceptive. Eur. J. Contracept. Reprod. Health Care 2001; 6 (I):

15-22.

Andersson K, Batar I, Rybo G. Return to fertility after removal of a

levonorgestrel-releasing intrauterine device and Nova-T.

Contraception. 1992;46:575-584.

Andersson K, Odlind V, Rybo G. Levonorgestrel releasing and copper

releasing (Nova T) IUD's during five years of use: a randomized

comparative trial. Contraception 1994; 49: 56-72.

Andersson K, Ryde E, Lindell K, et al. Perforations with intrauterine

devices. Report from a Swedish survey. Contraception.

1998;57:251-255.

Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in

treatment ofmenorrhagia. Br. J. Obstet. Gynaecol. 1990; 97: 690-

694.

Archer D, Kovacs L, Landgren BM, et al. Implanon, a new single-rod

contraceptive implant; presentation of clinical data. Contraception

1998; 58: 75-115.

Archer DF, Viniegra A, Hsiu JG, et al. Endometrial histology, uterine

bleeding and metabolic changes in postmenopausal women using

progesterone releasing intrauterine device and oral conjugated

oestrogens for hormonal replacement therapy. Menopause 1994;

1:109-116.

Azam ME, Kamal MM, Wafa GA, et al. Treatment of menorrhagia with

intrauterine administration of levonorgestrel. Egypt. J. Fertil. Steril.

1998; 2 (2): 55-64.

Azziz R. Adenomyosis: current perspective. Obstet. Gynecol. Clin. North

Am. 1989; 16(1); 221-235

Backman T, Huhtala S, Luoto R, et al. Advance information improves user

satisfaction with the levonorgestrel intrauterine system. Obstet.

Gynecol. 2002;99:608-613.

Baldwin RM, Whalley PJ, Pritchard JA. Measurement of menstrual blood

loss. Am. J. Obstet. Gynecol. 1961: 81:739-42.

Barbosa I, Olsson SE, Odlind V, et al. Ovarian function after seven years

use of a levonorgestrel IUD. Adv. Contraception. 1995; 11: 85 –95.

Barrington JW, Bowen SP. The levonorgestrel intrauterine system in the

management of menorrhagia. Br. J. Obstet. Gynaecol. 1997; 104 (5):

614-6.

Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with

intrauterine devices (levonorgestrel intrauterine device (LNG), CuT

380Ag, CuT 220C and CuT 200B). A 36-month study. Indian

Council of Medical Research Task Force on IUD. Contraception.

1989;39:37-52.

Bayer S, De Cherney AH. Clinical manifestations and treatment of

dysfunctional uterine bleeding. Am. J. Obstet. Gynecol. 1993;

269:1823-8.

Bjork J, Smedegard G. Acute microvascular effects of PAF-acether, as

studied by intravital microscopy. Eur. J. Pharmacol. 1983; 96: 87-94

Blesey EM. Vaginal bleeding patterns among women using one natural and

eight hormonal methods of contraception. Contraception 1988;

38:186-206.

Bonduella M, Walker JJ, Calder AA. A comparative study of danazol and

norethisterone in dysfunctional uteine bleeding presenting as

menorrhagia. Postgrad. Med. J. 1991; 67:833-6.

Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation:

randomized controlled trial of ethamsylate, mefenamic acid, and

tranexamic acid. Br. Med. J. 1996: 313:579-82.

Bonnar J, Sheppard BL, Dockeray CJ. The haemostatic system and

dysfunctional uterine bleeding. Res. Clin. Forum. 1983; 5: 27-36

Bouyer J, Rachou E, Germain E, et al. Risk factors for extrauterine

pregnancy in women using an intrauterine device. Fertil. Steril.

2000; 74: 899-908.

Brechin S, Cameron ST, Paterson AM, et al. Intrauterine polyps a cause of

unschedualed bleeding in women using Levonorgestrel intrauterine

system: Case report. Hum. Reprod. 2000; 15 (3):

650-2.

Bren L. Alternatives to hysterectomy: New Technologies, more

options.FDA Consum 2001;35:23-8. 30.

Brown PM, Farquhar CM, Lethaby A, et al. Cost-effectiveness analysis of

levonorgestrel intrauterine system and thermal balloon ablation for

heavy menstrual bleeding. Br. J. Obstet. Gynaecol. 2006; 113:797-

803.

Burhank F and Hutchins J. Uterine artery occlusion by remobilization or

surgery for treatment of fibroids: A unifying hypothesis transient

uterine ischemia. J. Am. Assoc. Gynecol. Laparosc. 2000: 4: SI-

S49.

Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial

comparing the levonorgestrel intrauterine system and thermal

balloon ablation for heavy menstrual bleeding. Br. J. Obstet

Gynaecol. 2006; 113:257-263.

Bussolat B, Dunk C, Grohman M, et al. Vascular endothelial growth factor

receptor-1 modulates vascular endothelial growth factor mediated

angiogenesis via nitric oxide.Am. J. Pathol. 2001; 159:993-1008.

Butler WJ. Normal and abnonnal uterine bleeding. In: Thaompson JD,

Rock JD (Eds), Telind Operative Gynecology, 8th Edition,

Philadelphia : Lippincott Ravin publisher 1997; 453 -475.

Caliskan E, Ozturk N, Dilbaz BO, et al. Analysis of risk factors associated

with uterine perforation by intrauterine devices. Eur. J. Contracept.

Reprod. Health Care. 2003;8:150-155.

Cameron I, Davenport A, Brown J, et al. Ednothelin-1 stimulates

prostaglandin F2α release from human endometrium. Prostaglandins

1991; 42:155-7.

Cameron I, Davenport A, Papendorp VC. Endothelin-like

immunoreactivity in human endometrium. J. Reprod. Fertil. 1995;

95:623-8.

Cameron IT. Dysfunctional uterine bleeding and menorrhagia. Clin. Obstet.

Gynaecol. 1989; 3: 315-327.

Cameron IT. The levonorgestrel intraulerine system: the benefits of reduced

bleeding. Eur. J. Contracept. Reprod. Health Care 2001; 6 (I):27-32.

Cameron IT, Haining R, Lumbsden AJ et al. The effects of mefenamic acid

and norethisterone on measured menstrual blood loss. Obstet.

Gynecol. 1990; 96: 85-88.

Cameron IT, Leask R, Kelly RW. The effects of danazol, mefenamic acid,

norethisterone, and a progesterone impregnated coil on endometrial

prostaglandin concentrations in women with menorrhagia.

Prostaglandins 1987; 34:99-110.

Cameron IT. Menstrual disorders. In: Edmonds DK (ed), Dewhurst's Text

Book of Obstetrics and Gynaecol for Postgraduate. 6th Edition.

Scientific Publication, Oxford London 1999: 410-19.

Cameron IT, Norman JE. Endometrial biochemistry in menorrhagia.Porg.

Report. Med. 1995: 2: 267-79

Campagnoli C, Lesca L, peris C. Long term hormone replacement treatment

in menopause. Lancet 1993 ; 18 (1): 21-46.

Camussi G, Aglietia M, Malavas F. The release of platelet- activating factor

from human endothelial cells in culture. J. Immunol. 1983; 131:

2397-2403

Carter CF. Endometrial ablation: more choices, more options. Hum.

Reprod. 2005; 30:35-40.

Casey M L, Hemsell D L, MacDonald P C, et al. NAD+dependent 15-

hydroxy-prostaglandin dehydrogenase activity in human

endometrium. Prostaglandins 1980; 19:115-122

Celik H, Sapmaz E. Use of a single preoperative dose of misoprostol is

efficacious patients who undergo abdominal myomectomy. Fertil.

Steril. 2003; 79(5): 1207-10.

Chapman DR, Key SM, Ryam JM. Uterine artery embolization for the

treatment of symptomatic fibroid disease. Applied Radiology 2001;

11-17.

Charnock JD, Sharkey AM, Rajpu J, et al. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol. Reprod. 1993; 48:1120-28.

Cheng, L, Kelly RW, Thong KJ et al. The effects of mifepristone (RU 486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. Hum. Reprod. 1993; 8:705-509.

Chimbira TH, Anderson AB, Turnbull AC. Relation between measured loss and the patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endomerrial surface area. Br. J. Obstet. Gynaecol. 1980a; 87: 603-609

Chimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. Br. J. Obstet. Gynaecol. 1980b; 87:1152-8.

Chrisman C, Ribeiro P, Dalton VK.The levonorgestril releasing intrauterine system:An updated review of the contraceptive and noncontraceptive uses.Clin. Obstet. Gynecol. 2007;50(4):886-

897.

Christiaens GC, Sixma JJ, Haspels AA. Hemostasis in menstrual endometrium: a review. Obstet. Gynecol. Survey 1982; 37:281.

Christiaens GC, Sixma JJ, Haspels AA. Morphology of haemostasis in menstrual endometrium. Br. J. Obstet. Gynaecol. 1980; 87: 425-430

Christiaens GC, Sixma JJ, Haspels AA. Fibrin and platelets in menstrual discharge before and after the insertion of an intra-uterine contraceptive device. Am. J. Obstet. Gynecol. 1981; 140: 793-798.

Clarke A, Black N, Rowe P, et al. Indications for and outcome of total abdominal hysterectomy for benign disease: A prospective cohort study. Br. J. Obstet. Gynaecol. 1995; 102:611-20.

Cohen I. Levonorgestrel releasing intrauterine device. Lancet 2001; 357:

801-805.

Cohen MA. Anaemia and menstrual blood loss. Obstet. Gynecol. Surv.

1980; 35: 597-601.

Coleman M. Me Cowen L, Farquhar C. The levonorgestrel releasing

intrauterine device: a wider role than contraception. Am. J. Obstet.

Gynecol. 1997:37 (2): 195-201.

Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual

blood loss. J. Obstet. Gynaecol. Br. Commonw 1971; 78: 933-939.

Collaborative Group on hormonal factors in Breast cancer. Breast cancer

and hormonal contraceptives: collaborative reanalysis of individual

data on 53,297 women with breast cancer and 100,293 women

without from 54 epidemiological studies. Lancet 1996; 347:1713-

1727.

Cooke I, Lethaby A, Farquhar C. Antifibrinolytics for heavy

menstrual bleeding (Cochrane Review). The Cochrane Library,Issue

4, 2000. Oxford: Update Software.

Cooper JM, Erickson ML. Global endometrial ablation technologies.

Obstet. Gynecol. Clin. North Am. 2000; 27:385-96.

Cooper KG, Parkin DE, Garnet AM, et al. Two-year follow up of women

randomized to medical management or transcervical resection of the

endometrim for heavy menstrual loss: clinical and quality of life

outcomes. Br. J. Obstet. Gynaecol 1999; 106:258-65.

Coulter A, Broadlow J, Agass M, et al. Outcomes of referrals to

gynaecology out-patient clinics for menstrual problems: An audit of

general practice records. Br. J. Obstet. Gynaecol. 1991; 98:789-96.

Coulter A. Prevalence and epidemiology of dysfunctional uterine bleeding.

In: Smith SK (ed) Dysfunctional uterine bleeding. London: Royal

Society of Medicine Press, 1994; 2-5.

Critchley HO, Wang H, Jones RL, et al. Morphological and functional

features of endometrial decidualization following long term

intrauterine levonorgestrel delivery. Hum. Reprod. 1998; 13: 1218-

1224.

Crosignani PG, Rubin B. Dysfunctional uterine bleeding. Hum Reprod

1990; 5:637-8.

Cunningham FG, Leveno KJ, Bloom SL, et al. Maternal anatomy,

Williams Obstetrics 22nd Edition, New York: McGraw- Hill 2005;

23.

Davey DA. Dysfunctional uterine bleeding. In: Whitfeild CR (ed)

Dewhurst's Text Book of Obstetrics and Gynecology, 5th Edition,

London: Blackwell science 1995; 590-608.

Davie J. New hormone delivery systems. Diplomate 1996; 3 (3): 184- 190.

Davis GK, Chapman (Eds). The menstrual cycle: the physiology of the

endometrium in: Scientific foundation of Obstet. and Gynaecol. 4th

edition, London: Butterwroth-Heinemam LTD 1992; 186-199.

DeLancey JL. Surgical anatomy of female pelvis. In: Rock JA and Jones

H.W, Eds. TE Linde's Operative Gynecology, 9th edition, Lippincott

Williams of willins, Philadelphia 2003; 69-102.

De Ziegler D, Bessis R, Frydman R. Vascular resistance of uterine arteries:

physiological effects of estradiol and progesterone. Fertil. Steril.

1991:55:775-9.

Diaz S, Pavez M, Cardenas H, et al. Recovery of fertility and outcome of

planned pregnancies after the removal of Norplant subdermal

implants or Copper-T IUDs. Contraception. 1987;35:569-579.

Dicker RC, Greenspan JR, Strauss LT, et al. Complications of abdominal

and vaginal hysterectomy among women of reproductive age in the

United States. A Collaborative Review of Sterilization. Am. J.

Obstet. Gynecol.1982; 144:841-8.

Doherty LB, Harper A, Russell M. Menorrhagia management options.

Fertil. Steril. 1995; 64:64-71.

Doll H, Vessey M, Painter R. Return of fertility in nulliparous women after

discontinuation of the intrauterine device: comparison with women

discontinuing other methods of contraception. Br. J. Obstet.

Gynaecol. 2001;108:304-314.

Downie J, Poyser N L, Wunderlich M. Levels of prostaglandins in human

endometrium during the normal menstrual cycle. J. Physiol. 1974;

236: 465-472

Drudy L, Sheppard BL, Bonnar J. Histamine concentration in plasma of

menstrual and peripheral blood in patients with normal menstrual

blood loss and in dysfunctional uterine bleeding.Br. J. Obstet.

Gynaecol. 1994; 14:435-7.

Duenas JL, Albert A, Carrasco F. Intrauterine contraception in nulligravid

vs parous women.Contraception. 1996;53:23-24.

Economos K, MacDonals PC, Casey ML. Endothelin-1 gene expression and

protein biosynthesis in human endometrium: potential modulator of

endometrial blood flow. J. Clin. Endocrinol. Metab. 1992:74:14.

Edwards JE, Moore A. Implanon: a review of clinical studies. Br. J. fam.

Plan. 1999; 24: 3-16.

El-Makhzangy IM, Hegab HM, Galal HM, et al. The effect of rectal

misoprostol on menstrual blood loss in menorrhagia. Egypt. J. Fertil.

Steril. 2003; 7(3): 55-61.

Erian J. Endometrial ablation in the treatment of menorrhagia. Br. J. Obstet.

Gynaecol. 1994; 101(suppl II): 19-22.

Eroglu K, Akkuzu G, Vural G, et al. Comparison of efficacy and

complications of IUD insertion in immediate postplacental/early

postpartum period with interval period: 1 year follow-up.

Contraception. 2006;74:376-381.

Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic

inflammatory disease: an international perspective. Lancet.

1992;339:785-788.

Farquhaw C. Management of dysfunctional uterine bleeding. Drugs 1992;

44:578-89.

Farrer BG, Beilby J, Tarbit M. Venous changes in the endometrium of

myomatous uteri. Obstet. Gynecol. 1971; 38:743- 51.

Fedele L, Bianchi S, Raftaelli R, et al. Treatment of adynomyosis

associated menorrhagia with a levonorgestrel releasing intrauterine

device. Fertil. Steril. 1997; 68: 426-29.

Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel releasing

intrauterine device in the treatment of rectovaginal endometriosis.

Fertil. Steril. 2001;75:485-488.

Fedorkow DM, Corenblum B, Shaffer EA. The use of gonadotrophin

releasing analog and transdermal estrogen to preserve fertility in

women with menorrhagia. Fertil. Steril. 1989; 52:512-3.

Floridon C, Lund N, Thomsen SG. Alternative treatment for symptomatic

fibroids. Curr. Opin. Obstet. Gynecol. 2001; 13:491 -5.

Fraser IS. Menorrhagia: a pragmatic approach to the understanding of

causes and the need for investigations. Br. J.Obstet. Gynaecol. 1994;

101, suppl.11,3-7.

Fraser IS. Hysteroscopy and laparoscopy in women with menorrhagia. Am.

J. Obstet. Gynecol. 1992; 162; 1264-1269.

Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine

bleeding with oral progestogens. Br. J. Obstet. Gynaecol.

1990,30:352-6.

Fraser IS. The dysfunctional uterus : dysmenorrhoea and dysfunctional

uterine bleeding. In: Shearman RP (ed) clinical reproductive

endocrinology. Edinburgh: Churchill Livingstone, 1985: 578-598.

Fraser IS, Baird DT. Blood production and ovarian secretion of estradiol-

17β and estrone in women with dysfunctional uterine bleeding. J.

Clin. Endocrinol. Metab. 1974; 39: 564-570.

Fraser IS, Hickey M, Song Y. A comparison of mechanisms underlying

disturbances of bleeding due to spontaneous dysfunctional uterine

bleeding and to hormonal contraception. Hum. Reprod. 1996; 11

(suppl 2): 165-178.

Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2

prostaglandin inhibiting agents in women with a complaint of

menorrhagia. Br. J. Obstet. Gynaecol. 1991; 31:66-70.

Fraser IS, McCarron G, Markham RA. Preliminary study of the factors

influencing perception of menstrual blood loss volume. Am. J.

Obstet. Gynecol. 1984; 149: 788-793.

Fraser IS, McCarron G, Markham R, et al. Blood and total fluid content of

menstrual discharge. Obstet. Gynecol. 1985; 65: 194-198.

French R, Van VH, Cowan F, et al. Hormonally impregnated intrauterine

systems versus other forms of reversible contraceptives as effective

methods of preventing pregnancy. Cochrane Database Syst Rev.

2004:CD001776.

Friedman AJ, Harrison Atlas D, Barbieri RL, et al. A randomized, placebo

controlled, double blind study,evaluating the efficacy of leuprolide

acetate depot in treatment of uterine leiomyomata. Fertil. Steril.

1989; 51:251.

Galle PC, McRae MA. Abnormal uterine bleeding. Postgrad. Med.

1993,93:73-76.

Gambrell RD. Progestogens in oestrogen replacement therapy. Clin. Obstet.

Gynecol. 1995; 38: 890-901.

Gannon MJ, Day P, Hammadieh N, et al. A new method for measuring

menstrual blood loss and its use in screening women before

endometrial ablation. Br. J. Obstet. Gynaecol. 1996; 103 (10):1029-

33.

Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from

tamoxifen stimulated changes by a levonorgestrel releasing

intrauterine system: a randomised controlled trial. Lancet.

2000,356:1711- 1717.

Garry R. Good practice with endometrial ablation. Obstet. Gynecol.1995;

85:144-51.

Garry R, Khair A, Mooney P et al. A comparison of goserlin and danazol as

endometrial thinning agents prior to endometrial laser ablation. Br.

J. Obstet. Gynaecol. 1996; 103:339-44.

Garry R and Phillips G. How safe is the laparoscopic approach to

hystetectomy? Gynaecol. Endosc.1995; 4:77-9.

Gonzalez D, Alvarez RB, Ochoa EP. Treatment of uterine leiomyomas with

luteinizing hormone releasing hormone antagonist Cetrorelix. Hum.

Reprod. 1997; 12:2028-35.

Gosling RG. Extraction of physiological information from spectrum

analysed doppler shifted continuous wave ultrasound signals

obtained noninvasively from the arterial tree. In Hill DW and

Watson BW (eds). Medial Electronic Monographs 13-22 Peter

Peregrinus, London 1979:73-125.

Graff IS, Tonstad S. Use of progestogen only contraceptives medications

and lipid parameters in women age 40 to 42 years; results of a

population based cross sectional Norwegian Survey.Contraception.

2002;66:7.

Graubert MD, Ortega MA, Kessel B, et al. Vascular repair after

menstruation involves regulation of vascular endothelial growth

factor receptor phosphorylation. Am. J. Patho.l 2001; 158:1399-410.

Grimes DA. Intrauterine device and upper genital tract infection. Lancet.

2000;356:1013-1019.

Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine

contraceptive device insertion. Cochrane Database Syst Rev.

2001:CD001327.

Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of

intrauterine devices. Cochrane Database Syst Rev. 2004:CD001777.

Grimes D, Schulz K, Van Vliet H, et al. Immediate post-partum insertion of

intrauterine devices. Cochrane Database Syst Rev. 2003:CD003036.

Grimes DA, Schulz KF. Prophylactic antibiotics for intrauterine device

insertion: A metaanalysis of the randomized controlled trials.

Contraception 1999; 60: 57-63.

Grunfeld L. The uterus and endometrium, vaginal ultrasonography for

practicing clinician. Clin. Obstet. Gynecol. 1996; 39:175-187.

Guillebaud J. Intrauterine contraception-what now and what next? Eur. J.

Contracept. health care 2001; 1:11-14.

Gu Z, Zhu P, Luo H, et al. A morphometric study on the endometrial

activity of women before and after one year with levonorgestrel

intrauterine system in situ. Contraception 1995; 52 (I): 57-61.

Hagenfeldt K, Landgren BM, Edstrom K, et al. Biochemical and

morphological changes in the human endometrium induced by the

progestassert device. Contraception 1977; 16: 183-197.

Hallberg L. Hogdahl A, Nilsson L, et al. Menstrual blood loss: a population

study. Acta. Obstet. Gynecol. Scand. 1966; 45: 320-351.

Hallberg L, Nilsson JL. Determination of menstrual blood loss. Scand. J.

Clin. Lab. Invest. 1964; 16:244-8.

Hart R, Magos A. The alternatives to hysterectomy. Clin. Obstet. Gynecol.

1999; 13:271-90.

Haspels AA. Emergency Contraception: a review. Contraception 1994;

90: 203-209.

HTAC. Surgical alternatives to hysterectomy for abnormal uterine bleeding.

Minnesota Health Technology Advisory Committee: 2000 June.

Available at: http://www.health.state.mn.us/htac/sah. htm.

Henzl MR, Corson SL, Moghissi K. Adminstration of nasal nafarelin as

compared to oral danazol for endometriosis. N. Eng. J. Med

1988;318:485-9.

Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss

using a pictorial chart. Br. J. Obstet. Gynaecol. 1990; 97:734-9.

Higham JM, Shaw RW. A comparative study of danazol, a regimen of

decreasing doses of danazol, and norethindrone in the treatment of

objectively proven unexplained menorrhagia. Am. J. Obstet.

Gynecol. 1993- 169:1134-9.

Hildlebaugh DA. Cost and quality-of-life issues associated with different

surgical therapies for the treatment of abnormal uterine bleeding.

Obstet. Gynecol. Clin. North Am.2000; 27:451-65.

Hofmann GE, Scott JR, Bergh PA, et al. Immuno histochemical

localization of epidermal growth factor in human endometrium,

Decidua and Placenta. J. Clin. Endocrin. Metab. 1991; 73:882.

Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility

follow up after participation in a randomized clinical trial.

Contraception. 2007;75:88-92.

Hubacher D, Lara R, Taylor DJ, et al. Use of copper intrauterine devices

and the risk of tubal infertility among nulligravid women. N. Eng. J.

Med. 2001;345:561-567.

Hurk P, O' Brien S. Non contraceptive use of levonorgestrel-reIeasing

intrauterine system . Hum. Reprod. 1999; 1: 14- 19.

Hurskainen R, Paavonen J. Levonorgestrel releasing intrauterine system in

the treatment of heavy menstrual bleeding. Curr. Opin. Obstet.

Gynecol. 2004; 16:487-490.

Hurskainen R, Salmi A, Paavonen J. et al. Expression of sex steroid

receptors and Ki-67 in the endometria of menorrhagic women:

effects of intrauterine Levonorgestrel. Mol. Hum. Reprod.

2000;11:1013-8.

Hurskainen R, Teperi J, Paavomen J, et al. Menorrhagia and uterine artery

blood flow. Hum. Reprod. 1999; 14(1): 186-9.

Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-

effectiveness of levonorgestrel releasing intrauterine system versus

hysterectomy for treatment of menorrhagia: a randomised trial.

Lancet. 2001;357:273-277.

Ignar TD, Nelson KG, Bidwell MC, et al. Coupling of dual signaling

pathways: epidermal growth factor action involves the estrogen

receptor. Clin. Obstet. Gynecol. 1992; 89: 658-662.

Irvine GA, Campbell BM, Lumsden MA. Randomised comparative trial of

the levonorgestrel intrauterine system and norethisterone for

treatment of idiopathic menorrhagia. Br. J. Obstet. Gynaecol. 1998;

105:592-8.

Janssen CAH, Scholten PC and Heintz PM. Reconsidering menorrhagia in

gynaecological practice. Is a 30 year old definition still valid? Eur. J.

Obstet. Gynecol. Reprod. Biol.1998;78:69-72.

Janssen CA, Scholten PC, Heintz AP. A simple visual assessment

technique to discriminate between menorrhagia and normal

menstrual blood loss.Clin. Obstet. Gynecol. 1995; 85:977-82.

Jarvella I, Tekay A, Jouppila P. The effect of a Levonorgestrel releasing

intrauterine system on uterine artery blood flow, hormone

concentrations and ovarian cyst formation in fertile women. Hum.

Reprod. l998; 12: 3379-83.

Jones K, Georgiou M, Hayatt D,et al. Endometrial adenocarcinoma

following the insertion of a Mirena IUCD Gynecol. Oncol.

2002;87:216-218.

Jones RL, Salamonsen LA, Critchly HO, et al. Inhibin and activin subunits

are differentially expressed in endometrial cells and leukocytes

during the menstrual cycle, in early pregnancy and in women using

progestin-only contraception. Mol. Hum. Reprod. 2000; (12): 1107-

17.

Julia O, Hilary C. Menorrhagia mechanisms and targeted therapies. Curr.

Opin. Obstet. Gynecol. 2005; 17(4):411-8.

Kammercr DN, Rogers RG. Endometrial ablation: electrocautery and laser

techniques. Clin. Obstet. Gynecol.2000; 43:561-74.

Kasonde JM. Effect of ethamsylate and aminocaproic acid on menstrual

blood loss in women using intrauterine devices. Br. Med. J. 1975; iv:

21-2.

Kaunitz AM. Injectable depot medroxyprogesterone acetate

contraception: an update for U.S. clinicians. Contraception. 1998;

43:73-83.

Kelleher C, Braude P. Recent Advances in Gynaecology. Br. Med. J. 1999;

319(7211):689-92.

Kooy J, Taylor N, Healy D. Ednothelial cell proliferation in the

endometrium of women with menorrhagia and in women following

endometrial ablation. Hum. Reprod. 1996; 11:1067-72.

Kovac SR, Christie SJ, Bindbeutel GA. Abdominal versus vaginal

hysterectomy: a statistical model for determining physician decision

making and patient outcome. Med. Decis. Making 1991; 11:19-28.

Lahteenmaki P, Rauramo I, Backman T. The levonorgestrel intrauterine

system in contraception. Clin. Obstet. Gynecol . 2000;65:693-697.

Lalonade A. Evaluation of surgical options in menorrhagia. Br. J. Obstet.

Gynaecol. 1994; 101, suppl.ll, 8-14.

Landstrom G, Wallin A, Landmark K, et al. The action of vasoconstrictive

agents on human tubal arteries. Hum. Reprod. 1999; 14:151-5.

Lethaby A, Augood C, Duchitt K. Nonsteroidal anti-inflammatory drugs for

heavy menstrual bleeding (Cochrane Review). The Cochrane

Library 2000a, Issue 4. Oxford: Update Software.

Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing

intrauterine systems for heavy menstrual bleeding. Cochrane

Database Syst Rev. 2005-.CD002126.

Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy

menstrual bleeding (Cochrane Review). In the Cochrane Library,

1999 .Oxford, Update software.

Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and

ablation versus hysterectomy for heavy menstrual bleeding

(Cochrane Review). The Cochrane Library 2000d, Issue 4. Oxford:

Update Software.

Liddell H. Menorrhagia. Hum. Reprod. 1993 ; 106 :255-7.

Livio M, Mannvcci PM, Vigauo G, et al. Conjugated estrogens for the

anagement of bleeding associated with renal failure. New Eng. J.

Med. 1986; 315:73.

Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and

continuation rates in women with symptomatic endometriosis

undergoing treatment with an intra uterine administered progestogen

(levonorgestrel): a 3 year follow-up. Hum. Reprod. 2005;20:789-

793.

Ludwig J C, Hoppens C L, McManus L M. Modulation of platelet-

activating factor (PAF)synthesis and release from human

polymorphonuclear leukocytes: role of extracellular albumin. Arch.

Biochem. Biophys. 1985; 241: 337-347

Lumsden M, Smith S. Menstruation and menstrual abnormalities. In:Shaw

RW, Soutter WP and Stanton SL (Eds), Text book of Gynecology;

1st edition. Churchill Livingstone 1992; 159.

Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception

with the levonorgestrel-releasing intrauterine device: 12 month

report of The European multicenter study. Contraception.

1987;36:169-179.

Luukkainen T, Pakarinen P, Toivonen J. Progestin releasing intrauterine

systems. Semin. Reprod. Med. 2001; 4: 355-65.

Machan L, Martin M. Uterine artery embolization to treat uterine fibroids.

Can. Assoc. Radiol. J. 2001; 52:183-7.

Magos AL. Management of menorrhagia Br. Med. J. 1990; 300: 1537-8.

Maia H, Maltez A, Coelho G, et al. Insertion of mirena after endometrial

resection in patients with adenomyosis. J. Am. Assoc. Gynecol.

Laparosc. 2003;10:512-516.

Marbaix R. Vekemans M, Galant C. el al. Circulating sex hormones and

endometrial stromelysin-1 at the start of bleeding episodes in

Levonorgestrel implant users. Hum. Reprod. 2000 suppi 3:120-34.

March CM. Bleeding problems and treatment. Clin. Obstet. Gynecol.1998 ;

41(4):928- 939.

Markee JE. Menstruation in intraocular endometrial transplants in the

rhesus monkey. Hum. Reprod. 1940; 28:219-308.

Marshall JK, Hunt RH. Hormonal therapy for bleeding gastrointestinal

mucosal vascular abnormalities: a promising alternative. Eur. J.

Gastroenterol. Hepatol. 1997; 9:521-5.

McKone E, Sheppard BL, Bonnar J. Uterine histology and menstrual blood

loss. Irish. J. Med. Sci. 1991; 160:359-60.

Meyer WR, Walsh BW, Grainger DA, et al. Thermal balloon and rollerball

ablation to treat menorrhagia: a multicenter comparison. Obstet.

Gynecol. 1998;92:98-103.

Miller RM, Frank RA. Zoladex (Goserelin) in the treatment of benign

gynecological disorders: an overview of safety and efficacy. Br. J.

Obstet. Gynaecol. 1992; 99: 37-41.

Milne SA, Jabbour HN. Prostaglandin F2α receptor expression and

signaling in human endometrium: role of PGF2α in epithelial cell

proliferation. J. Clin. Endocrinol. Metab. 2003; 88 (4): 1825-32.

Mishell DR. Noncontraceptive helath benefits of oral steroidal

contraceptives. Am. J. Obstet. Gynecol. 1982; 142:809-816.

Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an

intrauterine device increase the risk of pelvic inflammatory disease

among women with sexually transmitted infection? A systematic

review. Contraception. 2006;73:145-153.

Momtaz M, Zayed M, Rashid K. Doppler study of the uterine artery in

patients using an intrauterine contraceptive device. Ultrasound bstet.

Gynecol. 1994; 4:231-4.

Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone

treatment of early endometrial cancer. Am. J. Obstet. Gynecol.

2002,186:651-657.

Munro MG. Medical management of abnormal uterine bleeding. Obstet.

Gyaecol. Clin. North Am. 2000; 27:287-304.

Murphy AA, Kettel LM, Morales AJ. Regression of uterine leiomyoma in

response to anti-progesterone Ru 486. J. Clin. Endocrinol. Metab.

1993; 76:513-7.

Ndumbe FM, Husemeyer RP. Endometrial adenocarcinoma in association

with a levonorgestrel releasing intrauterine system (Mirena). J. Fam.

Plann. Reprod. Health Care. 2006;32:113-114.

Need JA, Forbes KL, Milazzo L, et al. Danazol in the treatment of

menorrhagia: the effect of a 1 month induction dose (200mg) and 2

month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo).

Br. J. Obstet. Gynaecol. 1992; 32:346-52.

Neven P, De Muylder X, Van Belle Y, et al. Tamoxifen and the uterus. Br.

Med. J. 1994; 309: 1313-1314.

Nilsson CG, Lahteenmaki PL, and Luukkainen T. Sustained intrauterine

release of levonorgestrel over five years. Fertil. Steril. 1986; 45:

805-807

Nilsson L, Rybo G. Treatment of menorrhagia. Am. J. Obstet. Gynecol.

1971; 110:713-720.

Nitu-Whalley IC, Lee CA Acquired von willebrand's syndrome report of 10

cases and review of the literature. Haemophilia 1999; 5:318-26.

Ojutiku D, Cutner A, Rymer J. Ectopic pregnancy with levonorgestrel

releasing intrauterine system. Br. J. Fam. Plan. 1998; 24 (2): 85-6.

Pakarinen P, Toivonen J, Luukkainen T. Therapeutic use of the

levonorgestrel intrauterine system, and counseling . Semin. Reprod.

Med. 2001, (4): 367-72.

Perino A, Quartararo P, Catinella E, et al. Treatment of endometrial

hyperplasia with levonorgestrel releasing intrauterine devices. Acta.

Eur. Fertil. 1987; 18:137-140.

Petrucco OM, Fraser IS. The potential for the use of GnRH agonist for

treatment of dysfunctional uterine bleeding. Br. J. Obstet. Gynaecol.

1992; Suppi 7:34-6.

Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a

levonorgestrel-releasing intrauterine system and a depot GnRH

analogue for the treatment of chronic pelvic pain in women with

endometriosis. Hum. Reprod. 2005;20:1993-1998.

Pickles VR, Hall WJ, Best FA, et al. Prostaglandins in endomerrium and

menstrual fluid from normal and dysmenorrhoeic subjects. J. Obstet.

Gynaecol. Br. Commonw 1965; 72: 185-192.

Prentice A . Medical management of menorrhagia. Br. Med. J. 1999 ;

319:1343-5.

Preston JT, Cameron IT, Adams EJ, et al. Comparative study of

tranexamic acid and norethisterone in the treatment of ovularory

menorrhagia. Br. J. Obstet. Gynaecol. 1995; 102; 401-406.

Quinn M, Neale BJ, Fortune DW. Endometrial carcinoma in pre-

menopausal women: a clinicopathological study. Gynecol. Oncol.

1985; 20: 298-306.

Radesie B, Sharma A. Levonorgestrel releasing intrauterine system for

treating menstrual disorders: a patient satisfactoion questionnaire.

Br. J. Obstet Gynaecol 2004; 44 (3): 247-51.

Rankin GLS, Veall N, Huntsman RG, et al. Measurement with chromium

of red cell loss in menorrhagia. Lancet 1962; 1:567-9.

Raudaskosi TH, Tomas EI, Paakkari IA, et al. Serum lipids and

lipoproteins in post-menopausal women receiving transdermal

oestrogen in combination with a Levonorgestrel releasing

intrauterine device. Maturitas 1995; 22: 47-53.

Rees MC, Anderson AB, Demers LM, et al. Endometrial and myometrial

prostaglandin release during the menstrual cycle in relation to

menstrual blood loss. J. Clin. Endocrinol. Metab. 1984; 58:813-8.

Rees MC, Parry DM, Anderson AB, et al. Immunohistochemical

localization of cyclooxygenase in the human uterus. Prostaglandins

1982; 23: 207-214.

Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a

pictorial chart: a validation study. Br. J. Obstet. Gynaecol. 2000;

107:320-2.

Rock G, Adamkiemcz T, Blanchette V. Acquired von willebrand's factor

deficiency during high-dose infusion of recombinant factor VIII. Br.

J. Haematol. 1996; 93:684-7.

Rodgers GM and Bithell TC. Disorders of hemostasis and coagulation. In:

Lee. GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM

(eds), Clinical Hematology, 10th edition, Williams and Wilkins,

Awaverly company 1999; 1694.

Rogers PA, Lederman F, Taylor N. Endometrial microvascular growth in

normal and dysfunctional states. Hum. Reprod. 1998; 4:503-8.

Rogovskaya S, Rivera R, Grimes DA, et al. Effect of a levonorgestrel

intrauterine system on women with type 1 diabetes: a randomized

trial. Obstet. Gynecol. 2005;105:811-815.

Ronnerdag M, Odlind V. Health effects of long term use of intrauterine

Levonorgestrel releasing system. A follow up study over 12 years of

continuous use. Acta. Obstet. Gynecol. Scand. 1999; 78: 716-721 .

Rose EH, Aledort LM. Nasal spray desmopression for mild haemophilia and

von willbrand disease. Am. Intern. Med. 1991;114:563.

Rosenberg MJ, Foldesy R, Nishell J, et al. Performance of the Tcu 380A

and Cu-fix lUD's in an international randomized trial. Contraception

1996; 53: 197.

Scarselli G, Tantini C, Colafranceschi M, et al. Levonorgestrel IUCD and

precancerous lesions of the endometrium. Eur. J. Gynaecol. Oncol.

1988;9:284-286.

Sculpher MJ, Dwyer N, Byford S. Randomised trial comparing

hysterectomy and transcervical endometrial resection: effect on

health related quality of life and costs two years after surgery Br. J.

Obstet. Gynaecol. 1996; 103: 142-9.

Senior J, Sangha R, Baxter GS, et al. In vitro characterisation of prostanoid

FP, DP, IP and TP receptors on the non-pregnant human

myometrium. Br. J. Pharmacol. 1992; 107:215- 21.

Sharkey AM, Day K, McPherson A. et al. Vascular endothelial growth

factor expression in human endometrium is regulated by hypoxia. J.

Clin. Endocrinol. Metab. 2000; 85:402-9.

Sharma SC, Sheppard BL, Bonnar J. Relationship of menstrual blood

loss with uterine 6-keto- PGF1 and TXB2 levels in women

with normal and dysfunctional uterine bleeding. Irish. J. Med. Sci.

1990; 159: 57.

Sharma SC, Sheppard BL, Bonnar J. Endometrial tissue levels of PGE2

and PGF2 metabolites in women with normal menstruation and

dysfunctional uterine bleeding. Irish. J. Med. Sci. 1990; 159; 152.

Shaw RW. Assessment of medical treatments for menorrhagia: Introduction.

Br. J. Obstet. Gynaecol. 1994; 101 :15-8.

Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing

hormone agonist in the treatment of menorrhagia. Br. J. Obstet.

Gynaecol. 1984; 91:913-6.

Shaw ST, Maeaulay LK. Morphologic studies on lUCD induced

metrorrhagia . Surface changes of the endometrium and microscopic

localization of bleeding sites. Contraception 1979; 19(1): 63-81.

Sheppard BL. The Pathology of dysfunctional uterine bleeding. Clin.

Obstet. Gynecol. 1984; 11:227-38.

Sheppard BL, Dockeray CJ, Bonnar J. An ultrastructural study of

menstrual blood in normal menstruation and dysfunctional uterine

bleeding. Br. J. Obstet. Gynaecol. 1983; 90: 259-265.

Shoupe D, Meme D, Mezro G, et al. Prevention of intrauterine hyperplasia

in postmenopausal women with intrauterine progesterone.N. Engl. J.

Med. 1991; 325: 1811-1821.

Sheth SS and Allahbadia GN. Diagnosis of dysfunctional uterine bleeding.

In: Sheth SS and Sutton CJ (Eds). Menorrhagia,1st edition, Isis

Medical Media 1999; 23-43.

Singer A, Ikomi A. Successful treatment of fibroids using an intrauterine

progesterone device. Acta. Obstet. Gynecol. Scand. 1994; 75: 124-

130.

Sivin I and Stern J. Health during prolonged use of levonorgestrel 20

micrograms/ day, and the copper T-cu 380 Ag intrauterine

contraceptive devices: a multicentre study. International Committee

for Contraception Research. Fertil. Steril. 1994; 61: 70-77.

Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with

levonorgestrel and with copper: a randomized comparison of the T-

Cu 380 Ag and levonorgestrel 20 mcg/day devices. Contraception.

1987;35:245-255.

Smith SJ. Uterine fibriod embolisation. Am. Fam. Physician.

2000;61(12):3601-11.

Smith SK. The pathophysiology of menorrhagia. In: Cameron IT, Fraser IS.

Smith S K (eds) Clinical disorders of the endometrium and the

menstrual cycle. Oxford: Oxford University Press, 1998:105-115.

Smith SK, Kelly RW. Effect of platelet activating factor on the release of

PGF2 and PGE2 by separated cells of human endometrium. J.

Reprod. Fertil. 1988; 82: 271-276.

Sowter MC, Singla AA, Lethaby A . Pre-operative endometrial thinning

agents before hysteroscopic surgery for heavy menstrual bleeding

(Cochrane Review). The Cochrane Library 2000, Issue 4. Oxford:

Update Software.

Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing ntrauterine

device in selected cases of myoma-related menorrhagia: a

prospective controlled trial. Gynecol. Obstet. Invest. 2005;59:29-35.

Speroff L, Fritz MA. Reproductive physiology, menstrual disorders,

dysfunctional uterine bleeding. Clinical Gynecologic

Endocrinology and infertility, 7th Ed Baltiomore: Lippincott

Willams& Willkins, 2005: 113-129, 331.499-9.

Speroff L, Fritz. MA. The Uterus. In: Weinberg (ed), Clinical Gynaecologic

Endocrinology And Infertility, 7th edition. Baltimore: Lippincott

Williams & Wilkins 2005a; 113-44.

Speroff L, Fritz MA. Dysfunctional uterine bleeding. In: Weinberg (ed),

Clinical Gynaecologic Endocrinology And Infertility, 7th edition.

Baltimore: Lippincott Williams & Wilkins. 2005b; 547-72.

Speroff L, Glass RH, Kase NG. Dysfunctional uterine bleeding. In:

Speroff L, Glass RH, Kase NG, editors. Clinical gynaecologic

endocrinology and fertility. 5th edition. Baltimore: Lippincott

Williams & Wilkins 2005 : 575-93.

Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices:

update and estimation of postfertilization effects. Am. J. Obstet.

Gynecol. 2002; 187: 1699-1708.

Stenchever MA, Drogemueller W, Herbst AL, et al. Comprehensive

gynecology. 4th ed. Philadelphia: Mosby 2001;1079-1097.

Stewart E, Novak R. Leiomyoma related bleeding: a classic hypothesis

updated for the molecular era. Hum. Reprod. Update 1996; 2:295-

306.

Studd J. Shifting indications for hysterectomy. Lancet 2002; 345: 388.

Sturridge F, Guillebaud J. Gynaecological aspects of the levonorgestrel

releasing intrauterine system. Br. J. Obstet. Gynaecol.1997; 104:

285-289 .

Suhonen SP, Holmstrom T, Allonen HO, et al. Intrauterine and subdermal

progestin administration in postmenopausal hormone replacement

therapy. Fertil. Steril. 2002; 63: 336-342.

Suvamto LE, Kauppila A. The levonorgestrel intrauterine system in

menopausal hormone replacement therapy: five – year experience.

Fertil. Steril. 1999; 72: 161-163.

Swartz DP, Butler WJ. Normal and abnormal uterine bleeding. In:

Thompson JD, Rock JA, editors. Te Linde's operative gynecology.

7th edition. Philadelphia: J.B. Lippincott Company, 1992:297-316.

Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of

menorrhagia in Chinese women: efficacy versus acceptability.

Contraception 1995; 51: 231-5.

Tewari R, Kay VJ. Compliance and user satisfaction with the intra-uterine

contraceptive device in family planning service. Eur. J. Contracept.

Reprod. Health Care. 2006;11:28-37.

Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot

gonadotrophin releasing hormone agonist and cyclical hormone

replacement therapy for dysfunctional uterine bleeding. Br. J.

Obstet. Gynaecol. 1996; 103:18-21.

Troche V, O’Connor DM, Schaudies RP. Measurement of human

epidermal growth factor receptor in the endometrium during the

menstrual cycle. Am. J. Obstet. Gynecol. 1991:165:1499.

Tillson SA, Marian M, Hudson R, et al. The effect of intrauterine

progesterone on hypothalamo-hypophyseal-ovarian axis in

humans.Contraception 1975; 11(2):179-192.

Turnbull AC, Rees MC. Gestrinone in the treatment of menorrhagia. Br. J.

Obstet. Gynaecol. 1990; 97:713-5.

Van Eijkeren M, Christiaens G, Haspels A, et al. Measured menstrual

blood loss in women with a bleeding disorder or usingoral

anticoagulant therapy. Am. J. Obstet. Gynecol. 1990; 162:1261-3.

Van Eijkeren MA, Christiaens GC, Scholten PC. Menorrhagia: Current

drug treatment concepts. Drugs 1992; 43:201-9.

Van Houdenhoven K, van Kaam KJ, van Grootheest AC, et al. Uterine

perforation in women using a levonorgestrel-releasing intrauterine

system. Contraception. 2006;73:257-260.

Vargraftig BB, Fouque F, Beneniste J. Adrenaline and PAF-acether

synergisc to trigger cyclooxygenase-independent activation of

plasma free human platelets. Hum. Reprod. 1982; 28:557-573

Varila E, Wahlstrom T, Rauramo I. A 5-year follow up study on the use of

Levonorgestrel intrauterine system in women eceiving hormone

replacement therapy. Fertil. Steril. 2001; 76 (5): 969-73.

Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel

releasing hormone system -a systematic enquiry and overview. Eur.

J. Obstet. Gynecol. Reprod. Biol. 2006; 125:9-28.

Varol N, Healey M, Tang P, et al. Ten- year review of hysterectomy

morbidity and mortality: can we change direction? Am. J. Obstet.

Gynecol. 2001; 41:295-302.

Vasilenko P, Kraicer PF, Kaplan R. A new and simple method of

measuring menstrual blood loss. J. Reprod. Med. 1988; 33:293-97.

Vercellini P, Aimi G, Panazza S, et al. A levonorgestrel-releasing

intrauterine system for the treatment of dysmenorrhea associated

with endometriosis: a pilot study. Fertil. Steril. 1999;72:505-508.

Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a

levonorgestrel-releasing intrauterine device versus expectant

management after conservative surgery for symptomatic

endometriosis: a pilot study. Fertil. Steril. 2003:80:305-309.

Vereide AB, Arnes M, Straume B, et al. Nuclear morphometric changes

and therapy monitoring in patients with endometrial hyperplasia; a

study comparing effects of intrauterine levonorgestrel and systemic

medroxyprogesterone. Gynecol. Oncol. 2003;91:526-533.

Vessay M, Huggins G, Lawless M, et al. Tubal sterilization: findings in a

large prospective study. Br. J. Obstet. Gynaecol. 1993; 90: 203-209.

Vessey MP, Lawless M, McPherson K, et al. Fertility after stopping use of

intrauterine contraceptive device. Br. Med. J. 1983;286:106.

Vilos GA, Lefebvre G, Graves GR . Lignes directrices sur la prise en charge

du saignement uterin anormal. J. Obstet. Gynaecol. 2001,23:710-6.

Walthen PL, Henderson MC, Witz CA. Abnormal uterine bleeding. Med.

Clin. North Am. 1995; 79:329-342.

Weeks AD and Duffy SR. Abnormal uterine bleeding: diagnosis and

management. In: Stud J (ed), progress in Obstetrics and Gynecology.

Churchill Livingstone 1996; 12:304-23.

Weston G, Rogers PA. Endometrial angiogenesis. Clin. Obstet. Gynecol.

2000; 14:919-36.

WHO. Medical eligibility criteria for contraceptive use. World Health

Organization ; 2004. Available at: http : // www. who.int/

reproductive - health/ publications /mec/7 iud.pdf . Accessed

January 10, 2007.

WHO. Cardiovascular diseases and use of oral and injectable progestogen

only contraceptives. Results of an international multicentre, case

control study. Contraception 1998; 57:315-324.

Wildemeersch D, Dhont M. Treatment of nonatypical and atypical

endometrial hyperplasia with a levonorgestrel releasing intrauterine

system. Am. J. Obstet. Gynecol. 2003,188:1297-1298.

Wildemeersch D, Batar I, Webb A, et al. The frameless intrautrine

contraceptive implant- an update for interval,emergency and post

abortal contraception. Br. J. Fam. Plan. 1999; 24: 149.

Williams P, Warwick R, Dysan M, eds. Gray's anatomy. 37th

edition.Edinburgh: Churchill Livingstone, 1989: 852.

Wolter SL, Stadberg E, Andersson K, et al. Intrauterine administration of

levonorgestrel 5 and 10 micrograms/24 hours in perimenopausal

hormone replacement therapy. A randomized clinical study during

one year. Acta. Obstet. Gynaceol. Scand. 1997; 76 (5): 449-54.

Working Party for Guidelines for the Management of Heavy Menstrual

Bleeding . An evidence based guideline for the management of

heavy menstrual bleeding , Br. Med . J.1999; 112:1747.

Worthington KR. Anatomy of the uterine artery. Am. J. Roentgenol.

2000; 174:258.

Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine

device on hormonal profile and menstrual pattern after long

term use. Contraception. 1995;51:359- 365.

Zinger M, Thomas MA. Using the levonorgestrel intrauterine System. Am.

J. Obstet. Gynecol. 2001; 2: 11-20.